Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy.
J Viral Hepat. 2000 May;7(3):203-10. Unique Identifier : AIDSLINE MED/20307923 Pradat P; Chossegros P; Bailly F; Pontisso P; Saracco G; Sauleda S; Thursz M; Tillmann H; Vlassopoulou H; Alberti A; Braconier JH; Esteban JI; Hadziyannis S; Manns M; Rizzetto M; Thomas HC; Tr:epo C; Department of Hepatology, H^otel-Dieu, Lyon, France.
Abstract:
To compare three quantitative assays measuring viral load in patients with chronic hepatitis C and to determine their value in predicting response to interferon (IFN) therapy, we analysed serum from 896 patients from eight European Centres using QUANTIPLEXtrade mark bDNA, MONITOR AMPLICORtrade mark and SUPERQUANTtrade mark assays. Analyses were performed on the same sample. Viral genotype was assessed using INNO-LiPA HCV II kits. Intercentre variations were observed that were related to the handling of specimens not processed and stored within 6 h of blood sampling. Among sera with optimal handling, a stronger correlation was observed between bDNA and SUPERQUANT (0.806) than between bDNA and MONITOR (0.677) and between MONITOR and SUPERQUANT (0.632). These discrepancies were greatest with genotype 2 (bDNA/SUPERQUANT= 0.772; bDNA/MONITOR=0. 456; SUPERQUANT/MONITOR= 0.299). This correlation was influenced by viraemia level and was better at lower viral loads. The proportion of sera with undetectable viral load was 15% with bDNA, 9.7% with MONITOR and 7.7% with SUPERQUANT. For the three measurements, the best cut-offs of sustained response to IFN treatment were located at their detection threshold. Among patients with viral load below the detection level, a sustained response was observed in 35% tested with bDNA, 38% with MONITOR and 80% with SUPERQUANT. Hence a stronger correlation was observed between bDNA and SUPERQUANT than between either of these assays and MONITOR. SUPERQUANT was the most sensitive assay and this greater sensitivity was associated with a better predictive value of treatment response.
Keywords: JOURNAL ARTICLE Antiviral Agents/*THERAPEUTIC USE Cohort Studies Comparative Study Genotype Hepatitis C-Like Viruses/GENETICS/*ISOLATION & PURIF Hepatitis C, Chronic/*DRUG THERAPY/VIROLOGY Human Interferons/*THERAPEUTIC USE Reagent Kits, Diagnostic RNA, Viral/ANALYSIS Support, Non-U.S. Gov't Treatment Outcome Viral Load 001030
A00A1124
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from
Elton John AIDS Foundation,
the National Library of Medicine,
and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
